Related Experiment Video
Updated: Jan 16, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A
Qiwen Li1, Honglian Ma2, Rongliang Zheng3
1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co, Ltd, Guangzhou, Guangdong, People's Republic of China.
Purpose:
Immunotherapy plus chemotherapy is the standard of care for driver-gene negative metastatic non-small cell lung cancer (NSCLC). Synchronous oligometastatic disease has a better prognosis than extensive metastasis, and the addition of stereotactic ablation body radiotherapy (SABR) results in improved efficacy. However, whether the combination of SABR with immunotherapy and platinum-doublet chemotherapy will lead to long-term disease control or even cure for patients remains unclear.
Methods And Materials:
This was a multicenter, phase 2, single-arm study to evaluate the efficacy and safety of durvalumab in combination with chemotherapy and SABR for oligometastatic stage IV NSCLC without previous systemic therapy. The primary endpoint was investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors version 1.1.
Results:
Thirty-five patients were enrolled in the study. Twenty-eight (80%) patients received radiation therapy, including 23 (65.7%) who received SABR. The median follow-up time was 24.7 months (95% CI, 21.6-27.5). In the full analysis set (n = 35), the median PFS (mPFS) was 10.4 months (95% CI, 4.4-26.1), and the 2-year PFS rate and overall survival (OS) rate were 38.5% (95% CI, 21.9-54.8) and 67.7% (95% CI, 49.0-80.7), respectively. In the per-protocol set (n = 32), mPFS was 14.6 months (95% CI, 4.7-26.1), and the 2-year PFS rate and OS rate were 42.4% (95% CI, 24.3-59.4) and 70.8% (95% CI, 51.2-83.8), respectively. The subgroup analysis showed that the mPFS was 24.3 months (95% CI, 7.6-NE) with SABR versus 3.1 months (95% CI, 1.4-4.7) without SABR (hazard ratio [HR], 0.2; 95% CI, 0.09-0.5; P < .001). Grade 3 or higher treatment-related adverse events (TRAEs) and immune-mediated adverse events (imAEs) were reported in 57.1% (20/35) and 25.7% (9/35) of patients, respectively.
Conclusions:
In oligometastatic NSCLC, the combination of durvalumab, chemotherapy, and SABR was effective and tolerable. Patients who did not experience disease progression after prior systemic therapy and received SABR might have optimal outcomes.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
